Table 4.
Previous studies.
| Authors | Patients, n | Primary tumor | Endovascular technique | Adverse events | Follow-up outcome |
|---|---|---|---|---|---|
| Huang et al.2 | 1 | Cervical squamous cell carcinoma | SG | None | None |
| Salaskar et al.6 | 1 | Rectal adenocarcinoma | Coil and Gelfoam embolization | None | Asymptomatic for 3 years |
| Chen et al.15 | 6 | Cervical cancer | Coil/PVA/NBCA embolization in all patients;SG in Patients 5 and 6 | Mild transient pelvic pain | Patient 1: 3.5 months/disease progressionPatient 2: 10.5 months/disease progressionPatient 3: 34 months/alivePatient 4: 5 months/disease progressionPatient 5: 3 months/bleedingPatient 6: 2.5 months/disease progression |
| Watarida et al.18 | 1 | Adenocarcinoma of the uterine cervix | Coil and Gelfoam embolization combined with FFB | None | None |
SG, stent graft; PVA, polyvinyl alcohol; NBCA, N-butyl-2-cyanoacrylate; FFB, femorofemoral bypass